NCT00660569

Brief Summary

The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
260

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2008

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 15, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 17, 2008

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
Last Updated

December 1, 2010

Status Verified

November 1, 2010

First QC Date

April 15, 2008

Last Update Submit

November 30, 2010

Conditions

Asthma

Keywords

asthma treatmentutilizationreal life practice

Study Arms (1)

1

Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Population treated by General Practitioner, Pneumologists or Paediatricians

You may qualify if:

  • Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

You may not qualify if:

  • Disability that, from investigator point of view, prevent from complying the follow up schedule
  • To have participated in any clinical study in the past 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Research Site

Barcelona, Barcelona, Spain

Location

Research Site

Sabadell, Barcelona, Spain

Location

Research Site

Alcorcón, Madrid, Spain

Location

Research Site

Leganés, Madrid, Spain

Location

Research Site

Madrid, Madrid, Spain

Location

Research Site

San Sebastián de los Reyes, Madrid, Spain

Location

Research Site

Murcia, Murcia, Spain

Location

Research Site

Olivares, Sevilla, Spain

Location

Research Site

Toledo, Toledo, Spain

Location

Research Site

Fuentes de Ebro, Zaragoza, Spain

Location

MeSH Terms

Conditions

AsthmaPatient Acceptance of Health Care

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Javier Nuevo Rivero

    AstraZeneca MC SpainEpidemiologyValue Demonstration Unit

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 15, 2008

First Posted

April 17, 2008

Study Start

January 1, 2008

Study Completion

February 1, 2009

Last Updated

December 1, 2010

Record last verified: 2010-11

Locations

ES(10)